Clinical Trials on Pulmonary Disease, Chronic Obstructive in Canada

Total 3349 results

McMaster University
St. Joseph's Healthcare Hamilton

Recruiting

Exploring the Utility of Hyperpolarized 129Xe MRI in Healthy Volunteers and Patients With Lung Disease

Bronchiectasis | Chronic Obstructive Pulmonary Disease | Asthma | Emphysema | Pulmonary Fibrosis | Alpha 1-Antitrypsin Deficiency | Bronchopulmonary Dysplasia | Sarcoidosis, Pulmonary

Canada
Boehringer Ingelheim

Completed

Efficacy and Safety Comparison of Tiotropium Inhalation Solution (Respimat Inhaler) and Spiriva HandiHaler in COPD

Pulmonary Disease, Chronic Obstructive

United States, Canada
Janssen Research & Development, LLC

Completed

A Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive | Asthma

United States, France, United Kingdom, Germany, Canada, Netherlands, Romania, Denmark
Universidad de Granada

Not yet recruiting

Task-specific Training for Patients With Acute Exacerbation of COPD (COPD)

Pulmonary Disease, Chronic Obstructive

Spain
Boehringer Ingelheim

Completed

Determining Optimal Free Dose Combination of Tiotropium Bromide and BI 1744 CL in Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Canada, Germany, Netherlands, Sweden
GlaxoSmithKline

Terminated

Dose Finding Study of Nemiralisib (GSK2269557) in Subjects With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Australia, Argentina, France, Germany, Poland, Romania, Russian Federation, Spain, United States, Netherlands, Sweden, Korea, Republic of, Canada, United Kingdom, Italy, Mexico
University of Calgary

Active, not recruiting

ENCOMPASS: Expansion Study B, RCT (ENCOMPASS)

Hypertension | Diabetes Mellitus, Type 2 | Chronic Kidney Diseases | Chronic Obstructive Pulmonary Disease | Asthma | Ischemic Heart Disease | Congestive Heart Failure

Canada
GlaxoSmithKline

Completed

Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Argentina, Chile, Romania, Canada
Boehringer Ingelheim

Completed

Respimat® Combivent Trial in Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Argentina, France, Greece, Korea, Republic of, New Zealand, Poland, Russian Federation, South Africa, Taiwan, Turkey, Ukraine, United Kingdom
GlaxoSmithKline

Completed

A 24-week Study to Compare Umeclidinium/Vilanterol (UMEC/VI), UMEC and Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Argentina, Canada, Germany, Spain, United States, Italy, Netherlands, South Africa, Sweden, France, Mexico, Australia
Boehringer Ingelheim
Pfizer

Completed

Trial Comparing Tiotropium Inhalation Capsules vs Placebo in Chronic Obstructive Pulmonary Disease (COPD).

Pulmonary Disease, Chronic Obstructive

United States, Belgium, Canada, Czech Republic, Germany, Greece, Netherlands, Portugal, Ukraine, United Kingdom
GlaxoSmithKline

Completed

A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Puerto Rico, United States, Australia, Argentina, France, Germany, Japan, Netherlands, Russian Federation, Spain, Ukraine, Finland, Czechia, Poland, Belgium, Chile, Peru, South Africa, Sweden, Thailand, Israel, Korea, Republic of, C... and more
GlaxoSmithKline

Completed

Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease (ESWT)

Pulmonary Disease, Chronic Obstructive

Canada, United States
GlaxoSmithKline

Completed

Survival Of Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Australia, France, Romania, Finland, Taiwan, Bulgaria, Estonia, Canada, Netherlands, Philippines, South Africa, Sweden, Spain, Singapore, Austria, Germany, Latvia, New Zealand, China, Ukraine, Thailand, Greece, United Kingdom and more
Boehringer Ingelheim

Completed

Effect of Treatment BI 1744 CL (5 and 10 mcg) Versus Placebo on Exercise Endurance Time During Constant Work Rate Cycle Ergometry II

Pulmonary Disease, Chronic Obstructive

Austria, Belgium, Canada, Germany, Russian Federation
Umeå University
Radboud University Medical Center; Centre de Recherche de l'Institut Universitaire... and other collaborators

Recruiting

Effect and Feasibility of Non-linear Periodized Resistance Training in People With COPD

Pulmonary Disease | Chronic Obstructive

Sweden, Canada, Netherlands
Boehringer Ingelheim

Completed

Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease I

Pulmonary Disease, Chronic Obstructive

Argentina, Brazil, Canada, Croatia, Czech Republic, Denmark, Finland, Germany, Hong Kong, India, Italy, Korea, Republic of, Malaysia, Norway, Philippines, South Africa, Spain, Sweden, Thailand, Ukraine
University of Calgary
University of Alberta

Active, not recruiting

ENCOMPASS: Expansion Study A, RCT (ENCOMPASS)

Hypertension | Diabetes Mellitus, Type 2 | Chronic Kidney Diseases | Chronic Obstructive Pulmonary Disease | Asthma | Ischemic Heart Disease | Congestive Heart Failure

Canada
Boehringer Ingelheim

Completed

Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)

Pulmonary Disease, Chronic Obstructive

United States, Australia, Austria, Canada, Germany, Greece, New Zealand, Norway, Slovakia, South Africa, Sweden
University of Calgary
Alberta Innovates Health Solutions; Canadian Diabetes Association

Active, not recruiting

Enhancing Community Health Through Patient Navigation, Advocacy and Social Support (ENCOMPASS)

Hypertension | Diabetes Mellitus, Type 2 | Chronic Kidney Diseases | Chronic Obstructive Pulmonary Disease | Asthma | Ischemic Heart Disease | Congestive Heart Failure

Canada
University of Calgary
University of Alberta

Active, not recruiting

ENCOMPASS: Expansion Study C

Hypertension | Diabetes Mellitus, Type 2 | Chronic Kidney Diseases | Chronic Obstructive Pulmonary Disease | Asthma | Ischemic Heart Disease | Congestive Heart Failure

Canada
Oregon Health and Science University
University of Colorado, Denver; University of Iowa; University of Wisconsin,... and other collaborators

Active, not recruiting

Team-based Versus Primary Care Clinician-led Advance Care Planning in Practice-based Research Networks

Cardiovascular Diseases | Cancer | Chronic Obstructive Pulmonary Disease | Frail Elderly Syndrome | Cerebrovascular Accident | Congestive Heart Failure

United States, Canada
GlaxoSmithKline

Completed

The Purpose of This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotriopium 18 mcg Once Daily Over a 24-week Treatment Period in Subjects With COPD

Pulmonary Disease, Chronic Obstructive

United States, Germany, Romania, Russian Federation, Spain, Bulgaria, Canada, Hungary, Argentina
GlaxoSmithKline

Completed

ADVAIR® DISKUS® Inhaler (Fluticasone Propionate/Salmeterol) Versus SEREVENT® DISKUS® Inhaler (Salmeterol) For The Treatment Of Chronic Obstructive Pulmonary Disease Exacerbations. ADVAIR® DISKUS® Inhaler and SEREVENT® DISKUS® Inhaler Are Trademarks of the GSK Group of Companies.

Pulmonary Disease, Chronic Obstructive

United States, Canada
Boehringer Ingelheim

Completed

Efficacy and Safety of 4 Weeks of Treatment With Orally Inhaled BI1744/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Belgium, Canada, Germany
Boehringer Ingelheim

Completed

Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease II

Pulmonary Disease, Chronic Obstructive

Argentina, Brazil, Canada, Czech Republic, Denmark, Finland, Germany, Hong Kong, India, Italy, Korea, Republic of, Malaysia, Norway, Philippines, Romania, Russian Federation, South Africa, Spain, Sweden, Thailand
University of Waterloo
YMCA; Royal Bank of Canada

Completed

Determining the Feasibility of Implementing a Combined Cognitive and Exercise Training Program for Older Adults in a Community Setting.

Obesity | Diabetes | Chronic Obstructive Pulmonary Disease | Fibromyalgia | Osteoporosis | High Blood Pressure | Osteo Arthritis | Joint Replacement | Stable Heart Conditions

Canada
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Terminated

Stage 1 Study of ARALAST NP and GLASSIA in A1PI Deficiency

Chronic Obstructive Pulmonary Disease | Alpha1-antitrypsin Deficiency

United States, Canada, Australia
Boehringer Ingelheim

Completed

Effect of Treatment BI 1744 CL (5 and 10 mcg) Versus Placebo on Exercise Endurance Time During Constant Work Rate Cycle Ergometry I

Pulmonary Disease, Chronic Obstructive

Australia, Austria, Canada, France, Germany
Gala Therapeutics, Inc.

Completed

Gala Treatment for Chronic Bronchitis in Canada

COPD | Chronic Bronchitis

Canada
Thunder Bay Regional Health Research Institute
Lakehead University; St. Joseph's Care Group; Thunder Bay Regional Health Sciences...

Recruiting

Developing Optimal Parameters for Hyperpolarized Noble Gas and Inert Fluorinated Gas MRI of Lung Disorders

Bronchiectasis | Chronic Obstructive Pulmonary Disease | Asthma | Obstructive Sleep Apnea | Emphysema | Pulmonary Fibrosis | Lung Cancer | Cystic Fibrosis | Mesothelioma | Pulmonary Hypertension | Interstitial Lung Disease | Pulmonary Embolism | Lung Resection | Lung Transplant | Seasonal Allergies | Lung Infection | Asbes... and other conditions

Canada
GlaxoSmithKline

Completed

Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Germany, Romania, Bulgaria, Argentina, Canada, Chile, Philippines, South Africa, Thailand, Netherlands, Korea, Republic of, Hungary, United Kingdom
Boehringer Ingelheim

Completed

Tiotropium+Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Argentina, Australia, Bulgaria, Canada, China, Czech Republic, Denmark, Estonia, Finland, France, Germany, Guatemala, Hungary, India, Italy, Japan, Korea, Republic of, Mexico, Netherlands, New Zealand, Portugal, Russian... and more
GlaxoSmithKline

Completed

Advair® DISKUS® Versus Serevent® DISKUS® For Chronic Obstructive Pulmonary Disease Exacerbations

Pulmonary Disease, Chronic Obstructive

United States, Canada
Pfizer

Terminated

A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics With COPD

Diabetes Mellitus | Chronic Obstructive Pulmonary Disease

United States, Canada, Brazil, Costa Rica, Germany
University of Minnesota
National Heart, Lung, and Blood Institute (NHLBI); Canadian Institutes of Health... and other collaborators

Terminated

Simvastatin Therapy for Moderate and Severe COPD (STATCOPE)

Pulmonary Disease, Chronic Obstructive

United States, Canada
AstraZeneca
Parexel

Completed

Observational Study of Obstructive Lung Disease (NOVELTY) (NOVELTY)

Chronic Obstructive Pulmonary Disease | Asthma | COPD

United States, Canada, Germany, Italy, Spain, United Kingdom, Mexico, Australia, Argentina, France, China, Japan, Brazil, Korea, Republic of, Colombia, Denmark, Netherlands, Norway, Sweden
Boehringer Ingelheim

Completed

Mechanisms of Dyspnea Relief During Exercise in COPD Patients Following Treatment With Tiotropium (Spiriva)

Pulmonary Disease, Chronic Obstructive

Canada
Danone Specialized Nutrition

Recruiting

Impact of a New Plant-based High-energy Oral Nutritional Supplement on Nutritional Outcomes in Malnourished Patients

Cancer | Inflammatory Bowel Diseases | Malnutrition | Hiv | Chronic Obstructive Pulmonary Disease (COPD)

Spain
GlaxoSmithKline

Completed

A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Germany, Japan, Russian Federation, Chile, Poland, Mexico, Estonia, Korea, Republic of, Philippines
GlaxoSmithKline

Completed

A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Australia, Argentina, Germany, Spain, South Africa, Mexico, Peru, Netherlands, Canada, United Kingdom, Denmark, Chile, Italy, Sweden
Novartis Pharmaceuticals

Completed

Study of Effect of CSJ117 on Symptoms, Pharmacodynamics and Safety in Patients With COPD

Pulmonary Disease, Chronic Obstructive

United States, Australia, Canada, Hungary, Japan, Czechia
University Health Network, Toronto
Canadian Institutes of Health Research (CIHR); Canadian Lung Association

Active, not recruiting

Identification of Patients Admitted With COPD Exacerbations and Predicting Readmission Risk Using Machine Learning

Machine Learning | Readmission | Copd Exacerbation Acute | Natural Language Processing

Canada
McGill University
Laval University; Mount Sinai Hospital, Montreal

Unknown

Pulmonary Rehab, Dyspnea, Walk and Step Testing in COPD

Pulmonary Disease, Chronic Obstructive

Canada
GlaxoSmithKline

Completed

Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)

Pulmonary Disease, Chronic Obstructive

United States
Sanofi

Terminated

KEYS: Study Comparing Clinical Health Outcomes of Telithromycin Versus Azithromycin in Outpatients With Community-acquired Lower Respiratory Tract Infections (KEYS)

Respiratory Tract Infections | Pneumonia | Chronic Bronchitis

United States, Canada
Boehringer Ingelheim

Completed

Tiotropium +Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Austria, Belgium, Brazil, Canada, China, Colombia, Croatia, Germany, Hungary, India, Ireland, Japan, Norway, Romania, Russian Federation, Serbia, Slovakia, South Africa, Spain, Sweden, Taiwan, Turkey, United Kingdom
GlaxoSmithKline

Completed

A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Argentina, Australia, Germany, Estonia, Chile, Netherlands, Peru, South Africa, Sweden, Mexico, United Kingdom, Italy, Philippines, Canada
Laval University

Recruiting

FreeDom: Innovative Strategy for the Management of COPD Exacerbations

Oxygen Deficiency | COPD Exacerbation

Canada
GlaxoSmithKline

Completed

An Efficacy Study of Umeclidinium/Vilanterol With Tiotropium/Olodaterol in COPD Patients

Pulmonary Disease, Chronic Obstructive

Germany, Spain, United States, United Kingdom

Clinical Trials on Pulmonary Disease, Chronic Obstructive in Canada

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ethiopia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations